

Reduction Act (PRA) (44 U.S.C. 3501 *et seq.*).

**DATES:** Comments must be submitted within 30 days of the date of this publication.

**ADDRESSES:** Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the *Attention:* NIH Desk Officer, Office of Management and Budget, at [OIRA\\_submission@omb.eop.gov](mailto:OIRA_submission@omb.eop.gov) or by fax to 202-395-6974.

To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact:

**FOR FURTHER INFORMATION CONTACT:** To request additional information, please contact Vivian Horovitch-Kelley, Program Analyst, Office of Management Analysis and Assessment, National Cancer Institute, 6116 Executive Boulevard, Suite 705, Rockville, MD 20892, or call non-toll-free number 301-435-8526 or e-mail your request, including your address to: [horovitchkellv@mail.nih.gov](mailto:horovitchkellv@mail.nih.gov).

**SUPPLEMENTARY INFORMATION:**

*Title:* Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery: National Cancer Institute (NCI). *Abstract:* The information collection activity will garner qualitative customer and stakeholder feedback in an efficient, timely manner, in accordance with the Administration's commitment to improving service delivery. By qualitative feedback we mean information that provides useful insights on perceptions and opinions, but are not statistical surveys that yield quantitative results that can be generalized to the population of study. This feedback will provide insights into customer or stakeholder perceptions, experiences and expectations, provide an early warning of issues with service, or focus attention on areas where communication, training or changes in operations might improve delivery of products or services. These collections will allow for ongoing, collaborative and actionable communications between the Agency and its customers and stakeholders. It will also allow feedback to contribute directly to the improvement of program management.

Feedback collected under this generic clearance will provide useful information, but it will not yield data that can be generalized to the overall population. This type of generic clearance for qualitative information

will not be used for quantitative information collections that are designed to yield reliably actionable results, such as monitoring trends over time or documenting program performance. Such data uses require more rigorous designs that address: The target population to which generalizations will be made, the sampling frame, the sample design (including stratification and clustering), the precision requirements or power calculations that justify the proposed sample size, the expected response rate, methods for assessing potential non-response bias, the protocols for data collection, and any testing procedures that were or will be undertaken prior fielding the study. Depending on the degree of influence the results are likely to have, such collections may still be eligible for submission for other generic mechanisms that are designed to yield quantitative results.

The Agency received no comments in response to the 60-day notice published in the **Federal Register** of December 22, 2010 (75 FR 80542).

Below we provide the National Cancer Institute projected average estimates for the next three years:

*Current Actions:* New collection of information.

*Type of Review:* New collection.

*Affected Public:* Individuals and households, businesses and organizations, State, Local or Tribal Government.

*Average Expected Annual Number of activities:* 15.

*Respondents:* 6,500.

*Annual responses:* 6,500.

*Frequency of Response:* Once per request.

*Average minutes per response:* Ranges from 30 minutes through 90 minutes.

*Burden hours:* 8,750.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget control number.

Dated: July 20, 2011.

**Vivian Horovitch-Kelley,**  
NCI Project Clearance Liaison, National Institutes of Health.

[FR Doc. 2011-19027 Filed 7-26-11; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**ADDRESSES:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

#### Wirelessly Powered MRI Signal Amplification System and Method

*Description of Technology:* The invention is in the field of MRI, and more specifically relates to device and method that may provide great improvements in the area of interventional MRI. The technology describes an MRI detection coil that has been integrated with a parametric amplifier to provide local signal detection fully integrated with amplification. This amplification is done in a way that is inherently wireless, thus enabling efficient signal transmission. The integrated MRI detector/amplifier can be used in a number of applications. First, it can replace conventional MRI amplification typically done with transistor, thus eliminating the need for wires. Second, it can replace what is traditionally used as part of implanted or catheter coils for interventional procedures with MRI. The advantage is that the signal can be amplified, and wireless transmission is part of the amplification scheme. Therefore signal can be transmitted from the subject in a way that provides detection at higher sensitivity than conventional coils without internal amplification.

*Applications:* MRI diagnostics and in particular in interventional MRI applications:

- The device can be used as part of a catheter MRI coil for MRI guided surgery.
- It can also be used as implantable NMR coils for localized spectroscopy with better sensitivity.
- The device can potentially be used as a free floating MRI detector/amplifier and swallowed for internal MRI detection as has been done quite successful with optical imaging devices for imaging the human intestine.
- There may be use in MRI coil arrays where interaction between wires in large element arrays is a problem.

*Advantages:*

- The detector/amplifier integrated system eliminates the need for transistors and is wireless, therefore heat is reduced and sensitivity of detection is increased.
- The system is compatible with interventional MRI devices.

*Development Status:*

- Proof of principle has been demonstrated on a prototype device.
- Testing a second generation device right now with smaller dimension that could be implanted into transplanted organs and used in mm sized catheters for interventional devices or the digestive tract.
- Plans to develop methods to decouple elements for use in MRI detector arrays.

*Inventors:* Chunqi Qian *et al.* (NINDS)

*Relevant Publications:*

1. Qian C, Murphy-Borsch J, Dodd S, Koretsky A. Local detection and parametric amplification of MRI signals. Abstract/Presentation, 52nd Experimental Nuclear Magnetic Resonance Conference, April 10–15, 2011, Pacific Grove, CA.
2. Qian C, Murphy-Borsch J, Dodd S, Koretsky A. Integrated detection and wireless transmission of MRI signal using parametric amplifier. Abstract/Presentation, 19th Annual Meeting & Exhibition of the International Society of Magnetic Resonance in Medicine, May 7–13, 2011, Montreal, Quebec, Canada.
3. Qian C, Murphy-Borsch J, Dodd S, Koretsky A. Sensitivity enhancement of remotely coupled NMR detectors using wirelessly powered parametric amplification. Magn Reson Med. 2011, under review.

*Patent Status:* U.S. Provisional Application No. 61/648,911 filed 29 Mar 2011 (HHS Reference No. E-113–2011/0–US-01).

*Licensing Status:* Available for licensing and commercial development.

*Licensing Contacts:*

- Uri Reichman, PhD, MBA; 301–435–4616; [UR7a@nih.gov](mailto:UR7a@nih.gov).
- John Stansberry, PhD; 301–435–5236; [js852e@nih.gov](mailto:js852e@nih.gov).

**An Antibody Specific for the Ubl4A Protein**

*Description of Technology:* The antibody developed against the Ubl4A protein is available for licensing. Ubl4A is involved in the proper targeting of tail-anchored proteins to membranes by acting as a chaperone to prevent inappropriate interactions or aggregation. Alterations in membrane insertion or protein degradation may be related to Ubl4a in certain disease states making Ubl4a an attractive biomarker for the study of disease development or as a tool for the development of assays for disease detection.

*Applications:* The Ubl4a-specific antibody detects Ubl4a in total cell lysates and tissues and can be used to study Ubl4a interactions with other proteins.

*Inventor:* Ramanugan Hegde (NICHD).

*Related Publication:* Mariappan M, Li X, Stefanovic S, Sharma A, Mateja A, Keenan RJ, Hegde RS. A ribosome-associating factor chaperones tail-anchored membrane proteins. *Nature*. 2010 Aug 26;466(7310):1120–1124. [PMID: 20676083].

*Patent Status:* HHS Reference No. E-058–2011/0—Research Tool. Patent protection is not being pursued for this technology.

*Licensing Status:* This technology is available as a research tool under a Biological Materials License.

*Licensing Contact:* Steve Standley, PhD; 301–435–4074; [sstand@od.nih.gov](mailto:sstand@od.nih.gov).

*Collaborative Research Opportunity:* The NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Ubl4A assay detection for disease diagnostics. Please contact Charlotte McGuinness at 301–435–3130 or [mcguinnnc@mail.nih.gov](mailto:mcguinnnc@mail.nih.gov) for more information.

**The Human Nuclear Co-Repressor Gene: Applications for Cancer Diagnostics/Therapeutics and Gene Expression Research**

*Description of Technology:* The human nuclear receptor co-repressor (huN-CoR) forms multimolecular complexes that alters chromatin structure, resulting in disrupted gene expression. The huN-CoR complex is central to normal processes such as erythropoiesis and thymocyte development, but is also linked to multiple cancers including colorectal carcinomas, endometrial cancers and

leukemia, particularly acute myeloid leukemia. Thus, huN-CoR is a potentially-valuable tool for cancer diagnosis, as well as a target for the development of huN-CoR-based cancer therapeutics. HuN-CoR is also an attractive research tool for the study of gene regulation, epigenetic modification and gene silencing.

The technology claims nucleic acid sequences comprising the huN-CoR gene and fragments thereof, as well as a gene chip array incorporating such fragments.

*Applications:*

- Target for novel anti-cancer therapies.
- Use as a tool for prognosis and diagnosis of HuN-CoR-related diseases.
- Use as a target for antibody production and development of biological assays to diagnose human disease related to HuN-CoR.
- Target for rational drug design of novel agents to reverse transcriptional repression
- Study of molecular repression of targeted genes using HuN-CoR fusion proteins.

*Inventors:* Johnson M. Liu and Jianxiang Wang (NHLBI).

*Related Publications:*

1. Wang J, Wang M, Liu JM. Domains involved in ETO and human N-CoR interaction and ETO transcription repression. *Leuk Res*. 2004 Apr;28(4):409–414. [PMID: 15109542].

2. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. *Proc Natl Acad Sci U.S.A.* 1998 Sep 1;95(18):10860–10865. [PMID: 9724795]

*Patent Status:* HHS Reference No. E-088–1999/0—U.S. Patent No. 6,949,624 issued 27 Sep 2005.

*Licensing Status:* Available for licensing.

*Licensing Contact:* Tara Kirby PhD; 301–435–4426; [tk200h@nih.gov](mailto:tk200h@nih.gov).

Dated: July 21, 2011.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2011–18966 Filed 7–26–11; 8:45 am]

**BILLING CODE 4140-01-P**